Danone S.A. (BN) Earnings Call Transcript & Summary

February 20, 2026

Euronext Paris FR Consumer Staples Food Products earnings 74 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, and welcome to Danone's 2025 Annual Results Conference Call. Right now, everyone is in a listen-only mode. Once the speakers have finished their presentation, we'll open things up for a question-and-answer session. If you'd like to ask something during that session, press *11 on your phone. You'll then get an automated message telling you that your hand has been raised. Should you want to take your question back, just press *11 once more. Please be aware that this conference is being recorded today. Joining us as speakers are Antoine de Saint-Affrique, our CEO, and Juergen Esser, our CFO. I'll now turn the conference over to Mathilde Rodié, Head of Investor Relations. Over to you.

Mathilde Rodié

executive
#2

Thank you, and good morning to all of you. I'm Mathilde Rodié, Head of Investor Relations. We appreciate your joining us this morning for the call on Danone's full-year 2025 results. Joining me are our CEO, Antoine de Saint-Affrique, and our CFO, Juergen Esser; they'll walk you through some prepared remarks and then take your questions. Before we begin, please note the disclaimer on slide 44 of the presentation, which covers forward-looking statements and the definition of the financial indicators we will reference during the presentation. With that, I'll turn things over to Antoine.

Antoine de Saint-Affrique

executive
#3

Thank you, Mathilde. Good morning, everyone, and a warm welcome to all of you. Thanks for being with Juergen and me today for our full-year results '25. Turning to slide three. Before we turn our attention to what is a very good set of results, I thought it was important to address the recent developments concerning infant milk formula. It is obviously front of mind for everyone, and first of all, and most importantly, for all the families who depend on us every day. I know how much the current events are disturbing and worrying for them. That is the last thing you want to go through when you are feeding the most precious person in your life. We obviously take this extremely seriously, and there, let me be clear. Food safety and quality are, have been, and will always remain our top priority at Danone. We are confident in the safety and quality of our products, which are backed by extensive scientific evidence and rigorous testing. In light of recent events, we went back to review the level of consumer complaints over the period in question, and we did not find any cause for concern. However, in the context of the ongoing evolution of authorities' requirements, we are working closely with those national food safety authorities, and are taking action to comply with their new requirements.

Antoine de Saint-Affrique

executive
#4

We've been recalling batches of infant formula products from the relevant markets — essentially in Europe and now in the Middle East. As we do that, our emphasis is on backing parents and healthcare professionals, giving them clear information, and helping rebuild trust, since that trust is what makes all the difference. Let me turn now to the results on slide four. It's a pleasure to share with you yet another set of strong results of good quality. What you're seeing on this chart goes beyond numbers printed on a page. They are a reflection of the hard work, the dedication, and the passion of the Danoners, and I truly want to thank every single one of them for it. '25 was the opening year of chapter two — our Renew strategy — and we delivered strong like-for-like sales growth of +4.5%. Crucially, that performance rested consistently on positive volume/mix across the whole year, which added +2.7% in '25. This quality growth, together with disciplined execution and ongoing productivity gains, produced a +44 basis points improvement in our recurring operating margin, which reached 13.4%, even as we kept investing behind our capabilities, our brands, our science, and our innovation. Our solid operational performance and strong financial discipline also showed up in recurring earnings per share, which grew +4.6% in '25 to reach €3.80 — close to an all-time high — along with a robust financial position and €2.8 billion in free cash flow generation.

Antoine de Saint-Affrique

executive
#5

Finally—though definitely not least—and completely in line with our goal of generating sustainable value, we took our ROIC higher again in '25. It now sits solidly in double-digit territory, up 62 basis points compared with last year. Another thing that matters here: we accomplished all of that while advancing sustainability in a focused, impactful manner, since we strongly believe it is vital for our business's long-term resilience. Once again this year, we earned recognition on the CDP AAA list, which speaks to our leadership in transparency and performance regarding climate, water stewardship, and forest preservation. On top of that, we obtained worldwide B Corp certification. That milestone represents the culmination of a journey spanning a decade and underscores our long-standing dedication to pairing strong business performance with positive social and environmental impact. All together, the '25 performance shown on this chart speaks to the strength and resilience of our unique health-focused portfolio. That performance ties closely to the structural trends currently reshaping the food industry. Let me move to slide five now. As I've told you previously, my view is that the food industry stands at a tipping point. Everywhere around the globe, people increasingly recognize that what they eat and their health are more connected than ever.

Antoine de Saint-Affrique

executive
#6

Consumers keep raising their expectations as they gain fresh understanding of what nutrition can do, and they're looking for better options for themselves and their families. Health through food has never mattered more. That's precisely the space where Danone is uniquely placed to lead. Our health-focused approach—backed by science and a strong emphasis on delivering high-quality offerings—uniquely positions us to supply nutritional solutions that help people at every stage of life. It isn't merely what we do; it's what consistently drives our strategy and execution. We're seeing the results. Our categories keep outperforming the broader food and beverage industry, powered by strong and converging trends that all point the same way. Consumers everywhere are choosing with health in mind. Take protein: it's essential for good health at every stage of life, and demand keeps climbing, especially among people using GLP-1 who are actively looking for ways to preserve strength. Today's consumers want more than just higher protein. They increasingly seek nutrient-dense, high-quality protein supported by the right dietary complements. Fibers play a critical role here. Most of the world's population consumes 20% to 30% less fiber than recommended, despite very strong evidence linking low fiber intake to a high risk of major non-communicable disease.

Antoine de Saint-Affrique

executive
#7

Fiber also plays an essential role in gut, immune, and metabolic health, and it assists the body in absorbing and utilizing protein more effectively. Protein and fiber together constitute a significant long-term growth opportunity, and we are reinforcing our leadership in line with that, drawing on our expertise in the area of biotics. Lastly, medical nutrition keeps showing its favorable effect on patients' lives. As we pointed out at our CMD in June '24, proper medical nutrition helps patients remain on their treatment over time, recover more effectively, particularly following surgery, and get back home sooner. Speeding recovery not only enhances patients' lives, it also brings clear health economic advantages for the healthcare system. All these trends together signal an obvious reality: people around the world now expect the food they eat to actively support their health, and that is precisely where Danone holds a unique position to lead. With close to 90% of our portfolio earning 3.5 stars or more under the Health Star Rating system, we provide everyday nutrition that is high in protein, rich in fiber, and grounded in biotics, together with our medical nutrition that makes a meaningful difference in people's lives. It's nutrition that tastes good. These enduring trends support our performance, as we can see on slide six.

Antoine de Saint-Affrique

executive
#8

For '25, like-for-like sales rose 4.5%, and the engine behind that has been our fast-growing platforms — high protein, gut health, infant formula, and medical nutrition stand out. Let's begin with high protein. That range is expanding quickly, and because the products are clearly superior and deliver functional benefits that set them apart, penetration keeps climbing across geographies, helped along by a steady stream of innovation rollouts. Oikos in the US brought in more than €1 billion of revenue in '25, which shows plainly how big and how relevant this platform is. The wider consumer move toward value-added dairy is lifting our Danone brand as well; with a stronger portfolio that now includes Skyr and Greek, the brand also went past the €1 billion revenue mark in '25, posting high single-digit growth for the year. Gut health and fiber are powerful growth drivers too, especially for Activia, where we've begun to win back our leadership position in gut health. Thanks to innovations in kefir and fiber-enriched products, Activia got back to growth in Europe in '25. Alpro, also in Europe, is another major growth engine. As the top plant-based brand and a billion-euro platform, we're building category momentum through innovation. We keep taking Alpro past being an ingredient-led dairy alternative and turning it into a benefit-led, plant-powered nutritional complement to dairy — which our newest packaging makes visible.

Antoine de Saint-Affrique

executive
#9

We're broadening what we offer, particularly in yogurts, so we can satisfy rising demand tied to flexitarian eating patterns. Within infant milk formula, the premiumization approach we've built around Aptamil kept producing robust outcomes in '25. Aptamil posted double-digit growth, made possible by renovating our core range and rolling out superior innovation that targets particular nutritional needs, which supports children's healthy growth and development. We kept widening our presence in markets too, extending the strong momentum we have in China and turning in outstanding results in India and throughout Southeast Asia — there, for example, the Aptamil business doubled in Vietnam within only one year. In medical nutrition, we're observing robust growth in both adult oral nutrition and tube feeding. Taken together, our flagship brands Fortimel and Neocate now form a billion-euro platform that is expanding quickly. We keep growing the portfolio, among other things through hybrid protein solutions built to enhance tolerance and adherence, which helps more patients obtain the nutrition support they require. As you can see, our growth engines are running strong and the momentum is unmistakable. What we deliver today is only one piece of the story. Turning to slide seven. At our last CMD, we laid out the ambition for Renew chapter two: going further on the fundamentals while continuing to transform the business.

Antoine de Saint-Affrique

executive
#10

Back in '25, that's what we began: rolling out science-based innovations, remaining faithful to our health-focused strategy, while shifting how we view our categories so we can unlock meaningful new opportunities. As I said earlier, fiber is essential for health, and late last year we introduced Oikos Fusion, a high-protein item enriched with prebiotic fibers that supports digestive health. It fits especially well with consumers trying to manage their weight, including people on GLP-1 medication. Along the same lines, Alpro just brought out its new meal-to-go drinks — nutritionally balanced, plant-based meal replacements built for busy lifestyles, delivering 20 grams of protein plus 26 essential vitamins and minerals. We're making the healthy choice the easy choice. We're also taking back our leadership where it counts most, starting with gut health. We're restoring Activia as the global benchmark in gut health. In markets like Japan and Australia, where we're winning, we capitalize on the fact that our Activia products contain probiotics up to 100 times stronger than regular yogurts, backed by scientific evidence and studies, and this is only the beginning. Lastly, we pledged to widen our channel footprint further to reinforce the resilience of our model even more, and that is happening.

Antoine de Saint-Affrique

executive
#11

During '25, channels beyond mass retail expanded at a notably quicker pace than mass retail did. Within our specialized channels — whether pharmacies, hospitals, or home care — we achieved double-digit growth. We're connecting with more individuals, across more locations, throughout every life stage. Turning to slide eight. Our attention stays fixed on execution and competitiveness, as we reinforce several of our core capabilities. On the operations side, we've achieved meaningful advances across recent years. We now function with enhanced agility and pace, and we take pride in our current 10th place standing in the Gartner Top 25 Supply Chains — the best ranking achieved by an FMCG company. During '25, we kept generating robust productivity improvements, underpinned by expanding digitization throughout our operations, all the way from the shop floor to the shelf. Our transformation is speeding up. With our Industry 5.0 approach, we're outfitting our teams and factories with sophisticated digital and AI-enabled capabilities — ranging from automated quality systems to predictive maintenance and real-time performance visualization. Our Industry 5.0 Academy is providing upskilling to 20,000 employees globally, while a network of 10 pioneering factories is testing our digital factory of the future. Past manufacturing, we're likewise reinforcing digital execution throughout our end-to-end value chain. AI-enabled planning hubs, increasingly automated shared service centers, and new in-store visualization tools are boosting the accuracy, speed, and efficiency with which we serve our customers and our shoppers.

Antoine de Saint-Affrique

executive
#12

Although we're seeing progress on several fronts, not all of it is functioning the way it ought to, and plenty of additional effort remains before underperforming areas are fixed. Clearly, in the US, how we performed in '25 fell short of what we expected. We aren't where we ought to be, and we recognize that we have to raise our game. To win here, it's not enough to go beyond protein or specialized nutrition; the rest of our portfolio has to be elevated too — from creamers to non-protein yogurt to plant-based — and we must show up in those spaces with the same strength and relevance we have today in high protein or SN. As you surely have noticed, we named a new Americas Zone President, Henri Bruxelles, and put broader organizational changes in place to rebuild a culture of winning, one rooted in execution excellence and the right operational intensity. Significant leadership change has been made, and we are beginning to deploy at pace innovation that has proven itself in other geographies and that aligns with consumer shifts. Beyond tackling underperformance, we're also widening our reach by investing to capture new growth tools. Capacity is being expanded where it matters most: in high protein, Skyr, kefir, Alpro, and medical nutrition across Europe, China, the US, and Japan.

Antoine de Saint-Affrique

executive
#13

What these investments will do is steadily open the door for us to seize growth opportunities in full, back the very strong demand we see in high protein, and let us serve emerging trends more effectively throughout the remaining categories. Now let's turn to slide nine. In order to sustain long-term performance and build a durable competitive advantage, we are reinforcing the capabilities that genuinely set Danone apart. Our view is that the future of dairy depends on empowering farmers to build supply chains that are more resilient and more sustainable. That is the reason we launched the Danone Milk Academy, a first-of-its-kind multi-year global platform that brings academia, technical partners, and Danone expertise together so farmers gain practical knowledge, science, and digital tools. With an approach tailored to different regions and to farm size, the Milk Academy will reinforce the dairy supply chain and speed up the long-term transformation of dairy farming. That same spirit is the foundation of our Partner for Growth initiative. More than a program, it acts as a catalyst for shared value, taking us from transactional relationships toward deep partnerships with our suppliers. Since it launched over two years ago, it has let us boost efficiency, unlock capacity, and push forward our sustainability goals. We are purposefully building a resilient, multi-sourced supplier ecosystem, combining the right diversity with the right quality, and partnering with suppliers who share a long-term, collaborative mindset.

Antoine de Saint-Affrique

executive
#14

It's also worth stressing that this way of working boosts our capacity to innovate and makes our supply chain sturdier. On the innovation front, we continue to put money into advanced research so we can build differentiation that lasts. We just opened our One Biome Laboratory in Saclay, which speeds up work on the gut microbiome by drawing on proprietary scientific data, clinical studies, and a deep grasp of consumers. We made an acquisition too, as the Akkermansia Company, adding a biotic strain with clinical proof behind it that could strengthen the gut barrier — a capability set to fuel more differentiation across our products going forward. Last, we keep putting resources into skills and leadership. With programs like DanSkills, our teams gain the capabilities that will matter tomorrow, and we push for steady upgrading in both functional and leadership terms. We're also carrying forward the cultural transformation that began four years ago — one built on a focus on execution and a passion for the consumer, and one in which performing and transforming go hand in hand. Let's turn to slide 10. Under Renew chapter two, we were also explicit that we would get onto the front foot with acquisitions. In '25, we began delivering on that ambition, with a strong emphasis on strategic fit and disciplined governance. After buying Kate Farms, we now hold a $500 million medical nutrition platform in the US — the first time we've reached meaningful scale and reach into the country's healthcare system and hospital infrastructure.

Antoine de Saint-Affrique

executive
#15

What matters here is that this platform rests on a product portfolio that is genuinely differentiated, meeting patient needs for nutrition that is more complete and healthier. Integration with the medical nutrition business we already have is going extremely well, and Kate Farms is delivering strong growth. Our ambition is clear: to build a powerful growth engine in North America and, in doing so, further rebalance our category mix in the US. We're also pleased that last week we acquired an additional 1% stake in our Australian dairy joint venture with Saputo, after exercising our call option. Concretely, this brings ownership to 51%, which results in financial consolidation of the business. Through three strong brands — YoPRO, Activia, and Ultimate — we operate dairy across Australia and New Zealand, and together they generate over €100 million in revenue in '25. We hold leading positions in both high protein and gut health, and interestingly, that is where our high-protein journey began as early as 2016, with the initial launch of YoPRO. Taken together, these moves illustrate how we are actively shaping our portfolio to support sustainable, long-term growth. With that, let me hand it over to Juergen. Juergen, over to you.

Juergen Esser

executive
#16

Thank you, Antoine, and good morning everyone. I'll begin the financial review by covering how sales performed, which is on slide 12. As the press release showed, we ended 2025 strongly, posting like-for-like sales growth of +4.7% during Q4 and wrapping up a year of steady execution. Crucially, volume/mix once again powered that growth at +2.5%, with price contributing +2.1% in Q4. As we roll out chapter two of Renew Danone, we draw on a well-diversified portfolio, turning in sustainable growth across regions and categories quarter after quarter. That picture gets even clearer on slide 13. For the full year, like-for-like sales rose +4.5%, with every region and every category pitching in. We'll get into regional specifics shortly, but let me flag the standouts now. First, Europe, which posted a very solid year, now with nine consecutive quarters of positive volume/mix and continued improvement in how its EDP portfolio is performing. The clear highlight of 2025 was CNAO, which turned in exceptional results across every sub-region, from China to Japan to Oceania. That said, it shouldn't overshadow how North America performed, which fell short of our expectations, as Antoine noted, particularly during the second half of last year, and it ranks as a key priority for improvement in 2026.

Juergen Esser

executive
#17

And then, looking at our newer markets across Latin America, Africa, and the Middle East—we don't discuss them very often, but it's worth noting they had a really strong 2025 and ended the year on a high note in Q4. You can see those regional trends mirrored in the growth we report by category as well. Within EDP, we had a very robust year at +3.5%, helped by a highly dynamic market backdrop worldwide. Specialized Nutrition posted like-for-like sales of +7.4%, which reflects robust demand for our infant milk formula and for our medical nutrition products alike. And finally, Waters grew +1.9% in 2025—a solid outcome given how uneven the weather was across different regions. Before I move into the regional review, I'd like to walk through our sales bridge for the year on slide number 14. The +4.5% like-for-like sales growth came from a +2.7% contribution out of volume/mix and +1.8% from price. Beyond like-for-like, currency had a negative 4.4% impact, driven by the euro strengthening against the majority of currencies. Scope came in slightly negative at -0.4%, which reflects the deconsolidation of Horizon Organic in early 2024, partially offset by the Kate Farms acquisition starting in the third quarter.

Juergen Esser

executive
#18

Overall, reported sales came in essentially flat at €27.3 billion. Now let's examine how each region performed, beginning with Europe on slide 15. In Q4, Europe upheld its favorable trend, posting like-for-like sales growth of +2.5%, with volume/mix still positive at +1%, while pricing added +1.5%. As the chart below shows, results held steady across the year as the team kept advancing the EDP portfolio transformation. In addition, during this final quarter, high protein, kefir, and skyr each posted double-digit growth. Meanwhile, our efforts on Activia—sharpening the focus on gut health and fibers—are beginning to deliver, as the brand achieved positive growth in Q4 throughout the region, including in key markets like France, the UK, or Spain. It's too early to claim victory, but the direction looks encouraging. Beyond Dairy, the plant-based portfolio kept up its strong showing, with Alpro once more delivering very robust, competitive growth. Specialized Nutrition's growth was powered chiefly by solid momentum in adult medical nutrition, with brands such as Fortimel and Nutrizon performing strongly. Our Waters category closed the year very strongly, driven in particular by Volvic through its innovations in flavored and functional water, and by the Evian brand as well.

Juergen Esser

executive
#19

Across the entire year, Europe posted like-for-like growth of +2.3%, supported by a 1.9% contribution from volume/mix, and its recurring operating margin climbed to 12%. That comes from combining a healthy gross margin gain—thanks to operating leverage—with considerable reinvestment in innovation and product superiority, which fuels growth momentum in the years ahead. Now let's turn to North America, slide number 16. The final quarter of the year was soft in North America, with like-for-like sales growth of +0.7%, driven by +1.3% price. Demand remains strong for our high-protein platform, which continues to grow at double-digit levels, backed by consumers shifting toward healthier choices. The Oikos brand keeps going from strength to strength, further expanding its market shares in the category. Unfortunately, the growth of Oikos is largely offset by the unsatisfactory performance of our plant-based and coffee creamers business. In coffee creamers, our market shares have been increasing progressively. We are, however, clear that we need to double down on our efforts to bring International Delight back to where it belongs. To address the fast-emerging clean label segment, we launched under the Too Good brand a new coffee creamers range offering low sugar levels with no artificial sweeteners.

Juergen Esser

executive
#20

For our coffee creamers business, 2026 is going to be a year of recovery and a return to growth—more specifically, starting in the second quarter, when the comparison base gets easier. Alongside EDP, our medical nutrition business posted a strong quarter. The legacy Nutricia business is performing well, with the Neocate brand leading the way, and Kate Farms, as Antoine mentioned, keeps scaling quickly as we move forward with the integration. That will become more apparent starting in the third quarter of 2026, when Kate Farms will be reflected in like-for-like. Across the full year, North America grew +2%, with volume/mix adding +0.6% and price adding +1.4%. Recurring operating margins were 11%, a decline of 39 bps, which reflects the investments required to rebuild top-line momentum. Let's move now to China, North Asia, and Oceania, on slide number 17. The CNAO zone had an exceptional year, finishing Q4 with like-for-like sales growth of +10.4%, driven entirely by volume/mix. We keep winning in Specialized Nutrition, where we delivered double-digit growth, with similar performance in infant milk formula and medical nutrition. Within IMF, Essensis continued to drive market share gains. With the category normalizing after the Dragon Year boost, we remain focused on our competitive performance.

Juergen Esser

executive
#21

Because of the excellent work done by Bruno and his team, we feel highly confident about our capacity to continue expanding via premiumization while further consolidating a market that remains fragmented. Alongside IMF, demand for our medical nutrition brands—particularly Fortimel and Neocate—stayed very strong, including during the year's final quarter. In EDP, Japan once again turned in an outstanding Q4 showing, powered by its two functional brands, Oikos and Activia. As Antoine noted, we are glad to be consolidating, going forward, the dairy joint venture that we operate in Australia. Australia resembles Japan in being a strongly functional market, one where platforms for high protein and gut health are flourishing—an encouraging sign for how our EDP category will perform down the road in that region. Lastly, within Waters, Mizone wrapped up a solid year, with steady results in Q4 during what is customarily a very small quarter for this category. We have deliberately brought stocks down to minimal levels because, at this very moment, we are launching several renovations with Chinese New Year as we prepare for the 2026 season. Across the full year, CNAO sales rose +11.7%, driven entirely by volume/mix of +12%. Recurring operating margin came in somewhat lower at 29.2%, which mirrors higher investments aimed at supporting additional market share gains, especially in Specialized Nutrition and in Waters.

Juergen Esser

executive
#22

Moving on to Latin America, which you can see on slide 18. Q4 was a strong quarter for the region, posting like-for-like sales growth of +8.3%, mostly driven by price. EDP put up competitive growth right across the region, and I'd like to call out in particular the Danone brands along with the high-protein platforms, namely Oikos and YoPRO. Specialized Nutrition maintained its solid momentum, powered by Aptamil and medical nutrition spanning both pediatrics and adult ranges. And finally, Waters, which came back to growth in Q4 following a tough season. For the full year, Latin America posted +6% like-for-like growth. We're making solid headway on the region's margins, and recurring operating margin rose substantially to 6.4%, almost 3 points above where it stood a year ago. That came from underlying margin improvement together with IAS 29 effects turning positive. Last, let's turn to our AMEA region on slide number 19. The region finished 2025 on a strong note, with like-for-like sales growth of +8.3% in Q4, of which +5.5% came from volume/mix. Within EDP, Dairy Africa kept delivering strong volume/mix-led growth. Specialized Nutrition posted double-digit growth, with strong results across every sub-region. The Aptamil brand continued to gain market shares, and we see plenty of headroom to expand further in the region.

Juergen Esser

executive
#23

Across the entire year, AMEA posted like-for-like growth of +5.6%, consisting of +2.1% from volume/mix and 3.5% from price. Our recurring operating margin held firm at 10.4%. I'd propose we wrap up the regional performance review at this point, and therefore let's proceed to the full-year 2025 margin bridge, which is on slide number 20. In 2025, our recurring operating margin rose by +44 bps, arriving at 13.4%. Once again, the biggest contributor was margin expansion from operations, at +77 bps. That mirrors our emphasis on volume-led growth, along with ongoing productivity improvements throughout our cost of goods sold. True to our business model, we keep reinvesting in our brands and products so as to fuel future growth avenues and drive category leadership. As anticipated, these reinvestments eased in year 2025 relative to earlier years. Finally, there is the contribution from other effects, which primarily captures the favorable impact of applying IAS 29. The robust margin gain in year 2025, paired with our strong like-for-like sales growth, served as the principal driver behind our recurring EPS performance. Let's turn to the following slide, slide 21, for the details. In hard currency last year, our recurring EPS climbed +4.6%, to €3.80.

Juergen Esser

executive
#24

Solid operational results, which we covered earlier, drove the +5.9%. EPS was modestly pressured by refinancing costs that came in higher and by the full effect of divestments made in 2024, though tax, associates, and minorities partly made up for that. The hit from currency was mostly countered by IAS 29. We're very happy to say that our value creation pledge is being met across every key financial perimeter, so I'd propose we turn to the following slide, slide 22, where you'll get further detail. Free cash flow of €2.8 billion was delivered last year, a reflection of robust operations and tight financial discipline. Importantly, we generated that strong cash flow even as we raised our investments in the business, and we never compromised on what will forever be our top capital allocation priority. In 2025, as anticipated, we lifted our capex spendings, concentrating on building capacity for medical nutrition and functional dairy. That powerful cash generation let us go after targeted M&A, among them the purchase of the Kate Farms company, while at the same time bringing our leverage down a bit. We're also very glad to have pushed our return on invested capital even higher, to 10.7%. Growing ROIC and holding it structurally at double-digit levels matters greatly in our value creation journey.

Juergen Esser

executive
#25

To wrap up, I want to note that we'll be putting forward a dividend of €2.25 per share, which is roughly 5% higher than the prior year and moves in step with EPS growth. Given these robust results, we feel confident about our capacity to fulfill our ambition of creating future value, which brings me quite naturally to my final slide, slide number 23, covering our financial guidance. Consistent with our mid-term guidance, our target for year 2026 is net sales growth of +3% to +5% like-for-like, alongside recurring operating income expanding at a quicker pace than sales. Having said that, I'll pass it back to Antoine for the conclusion.

Antoine de Saint-Affrique

executive
#26

Thank you, Juergen. As we wrap up this call, and before we open things up for questions, I'd like to share a few closing thoughts — and let's go right to slide 25. Staying consistent in how we perform while we keep transforming the company remains our top priority. We do this by innovating and making disciplined acquisitions, setting the business up for what lies ahead, and picking our spots to seize opportunities in an environment that changes quickly. High-growth, value-added segments stay our focus, since there science and health-related benefits clearly set us apart. Through disciplined execution we are committed to quality results — repairing whatever requires repair, expanding what is working, and keeping a mindset of constructive dissatisfaction in a world that grows more complex. All of this reflects our ambition to be a genuine value compounder, creating sustainable value over the long term, while staying resilient through ongoing volatility. Looking toward '26, even with the external environment still uncertain, our approach stays the same. We remain disciplined, we keep our attention on execution, and we stay aligned with the mid-term ambition we have laid out. With that, I'll turn it back to Mathilde to begin the Q&A. Mathilde, over to you.

Mathilde Rodié

executive
#27

Thanks a lot. At this point we’re set to begin the Q&A, and the first question comes from Guillaume Delmas at UBS.

Guillaume Delmas

analyst
#28

Mathilde here, and good morning to Antoine and Juergen. Two questions from me. First, on your operating margin in EDP. If I recall correctly, ever since the 2022 reset, when Renew Danone was first introduced, EDP margins haven't really improved in any meaningful way, and they're still well under the 10% mark. So my question is this: relative to what you originally expected back in 2022, is EDP profitability running somewhat behind schedule? Why aren't you seeing the strong volume/mix development and the productivity savings lifting the division's margins a bit more? And looking ahead, what do you think the medium-term margin profile for this business looks like? Is it around 10%? Might it go even higher? Any color on that would be very helpful. My second question probably won't surprise you — it's on the IMF recall. I appreciate that this morning it's too early to quantify the impact, but maybe you can talk about what empirically you've seen so far? Any shortages or issues with on-shelf availability, any consumer hesitancy towards your brand? Zooming in on mainland China, where I don't think you had any product recalls, did you actually benefit from competitors' recalls in the first weeks of 2026?

Guillaume Delmas

analyst
#29

I appreciate that.

Antoine de Saint-Affrique

executive
#30

Thank you, Guillaume. Well, as we normally do, Juergen and I will present this together, and I'll begin with the question you just raised. First of all, incidents of this type aren't really welcome news for the category as a whole. As far as China goes, not a single one of the products we offer through official direct channels there has been affected, and of course we're cooperating with the Chinese authorities with complete, complete openness. Turning to Europe, we anticipate — and we are in fact seeing — disruption to supply. Naturally, there's a great deal of activity on our consumer carelines. We're also seeing sentiment that is, in fact, balanced. Of course, the first recall brought plenty of emotion. As I mentioned, incidentally, prior to that recall we reviewed all of our consumer complaints and found nothing. The whole organization is focused on essentially two things: ensuring the products return to shelf, and ensuring we reassure consumers as well as healthcare professionals, who are very active, both online and on our careline. As for the lasting effect on consumer sentiment in Europe, it's too soon to tell. We haven't observed anything that strikes us as simply extraordinary.

Antoine de Saint-Affrique

executive
#31

You might have noticed that EFSA published something yesterday — I'd point you toward that — and in it they assessed exposure as being low to moderate for infants. That should also help give consumers reassurance.

Juergen Esser

executive
#32

Good morning, Guillaume. This is Juergen. On the financial impacts, there are two, three important elements. First, since most batches currently being recalled were already sold during the course of year 2025, we have not experienced a significant return of stock today. So, while the recalls are under way, the current financial impacts on year 2025 do not seem material to us. That said, and to your point, the recall of several industry players at the same time has created some disruption on the shelf, especially in European retailers, because some retailers were first taking off all the products before sorting and replenishing the shelf. We expect that supply disruption to have a one-off impact on our Q1 performance, and we estimate this one-off impact to be between 0.5% to 1% of net sales in the first quarter. Moving forward, as Antoine said, our ambition is to win back trust and credibility, because it is extremely important in that category. It's obviously very early days. We need to monitor the situation very closely, but the few data points that we have on market shares are rather reassuring. On EDP margins, you are absolutely right that the key focus for us, and you may remember that when we were together launching the chapter two of Renew Danone, we were very clear on what we are expecting from EDP in terms of contribution on growth, and I think we are delivering on a very nice way on it, with +3.5% in year 2025, 2025, as much as on margins, because we declared very clearly that EDP margins target is to go into double-digit territory.

Juergen Esser

executive
#33

That isn’t showing up yet in the category’s EBIT figures, since we’re putting substantial investment behind that growth. Gross margins are rising, and you’re seeing the company’s gross margins climb with major support from higher EDP gross margins, while at the same time we’re feeding the growth. As Antoine mentioned, we’re feeding growth in Europe through everything we’re doing on Activia, high protein, skyr and kefir, and just as importantly, we’re refueling growth in North America across the full EDP portfolio.

Antoine de Saint-Affrique

executive
#34

As we've consistently said, I believe we'll continue reinvesting to fuel growth in our category—and where we've become less competitive, to restore our brand's strength and competitive edge. Regarding Activia, which I mentioned, it's gradually returning to growth through solid innovation and by reintroducing the gut challenge. We're seeing movement in a positive direction. We'll keep putting investment behind it to ensure we reclaim and regain leadership in that area, since we're convinced it's the field of the future.

Guillaume Delmas

analyst
#35

Thanks a lot.

Mathilde Rodié

executive
#36

Thanks, Guillaume. We’ll take the next question from Celine Pannuti at JPMorgan.

Céline Pannuti

analyst
#37

First off, I'd like to revisit your comments on infant milk formula and get some clarification. You cited an impact of 50 to 100 basis points in Q1 — is that at the group level, or does it apply to Europe? Next, on market share performance, what are you seeing? I realize it's early, but how are things trending for you in Europe, or in China? Then, Antoine, I believe you said this isn't great news for the category. Looking at the mid-term, how do you see this playing out — through higher regulation, or perhaps more consolidation? I'd be interested in your perspective on that. My second question concerns North America, where volume turned negative in the fourth quarter. You said capacity is on the way, and that a creamer is also becoming more competitive. How should we think about volume reaccelerating through 2026? Thank you.

Antoine de Saint-Affrique

executive
#38

Hi, Celine. We’ll do a duet once more. We’ll do a duet again. I’ll begin with IMF, where we’ll do a duet, and then we’ll return to the US. On shares, we didn’t observe—it’s too early to say. We saw no meaningful share shift in either direction. What I was saying is that this isn’t good for the category. You don’t win on events. You win on science, you win on competitiveness, you win by being best at execution. Short-term shares gained or lost on an event is not—it isn’t good news. It’s not something structural. We don’t see anything major, but it’s very, very—it’s very, very early. IMF is a very, very regulated category. I think in our factories, we have more than 300 checkpoints for quality. There are rules in every country that are extremely, extremely strict. Do we expect regulation to strengthen further? Not in any major and significant way. There has been a change in the rules and regulation regarding cereulide, and that has been an ongoing move over the last couple of weeks.

Antoine de Saint-Affrique

executive
#39

Overall, we don’t anticipate that the category rules will change. Where we feel very sure, frankly, is in how good our product is; we’re extremely close to both consumers and healthcare professionals, and our innovation is genuinely distinctive. It’s too early to tell, and we’re not seeing any meaningful effect. We’ll have to put in work, since noise surrounding the category is never welcome news, but I don’t view this as structural.

Juergen Esser

executive
#40

Morning, Celine. This is Juergen. On the financial side, I can confirm the 50 to 100 bps impact on Q1 at the group level, but as you noted, ultimately it's showing up in the Europe and Middle East region, since that's where the recalls are taking place. We anticipate things will get back to normal during the course of March.

Antoine de Saint-Affrique

executive
#41

Regarding the US, I want to be very clear: I am not pleased with how we are performing. There are areas where we are extremely pleased. High protein continues to perform strongly. Everything in medical nutrition is performing exceptionally well. Kate Farms continues to go from strength to strength. Our Nutricia business also continues to go from strength to strength. That, I find very exciting. We have a couple of positive developments that are coming on stream. We are seeing some early green shoots in creamers. We have launched Too Good in natural, but honestly, I believe we will only see progress later in the year, from quarter two onwards. We are relaunching Danimals, but more work remains to be done. I have not been happy with Silk for a while now. I think we made choices in the rest of yogurt because we did not have enough capacity. Capacity is coming on stream, and we should improve, but we could have done better. There has been a really deep change in leadership in the US, obviously with Henri, who brings deep knowledge and a huge track record, but beyond Henri, we went very deep in leadership change in the US. The lady who has been running the turnaround of Alpro in Europe is now in charge of the category and of the creamers in the US.

Antoine de Saint-Affrique

executive
#42

I’m looking for North American drama to wrap up, and for the US to move quickly.

Juergen Esser

executive
#43

Perhaps one more point worth adding: there's still 1 more quarter remaining in which we're up against tough prior-year comparisons for coffee creamers. Starting with Q2, that pressure will let up, and it should also support the rebound in that region.

Céline Pannuti

analyst
#44

Much appreciated.

Mathilde Rodié

executive
#45

Thanks, Celine. Our next question comes from Jon Cox at Kepler. Jon?

Jon Cox

analyst
#46

Yes. Morning, everyone. Apologies, I just want to return to that 50 to 100 basis points point. What you're describing applies across the whole group, not only Specialist Nutrition — group-wide, 50 to 100 basis points in Q1, and at the 100 basis points level that works out to 25 basis points for the year. That looks fairly material to me. I realize it may not be by the time it reaches EPS level, but it still looks quite material. And that's only the recalls themselves, not counting, say, any brand damage in Europe caused by those recalls. Let me add to that — regarding elsewhere, you mention the Middle East recalls: is there any indication that governments in other parts of the world will adopt European standards, and what would the impact be when it comes to possible recalls in Asia and other regions? My second question is on the gross margin gain, which I can see is 90 basis points. It connects to the earlier question about EDP margin simply not moving, and I believe most of us assumed that would be what drove overall group margin improvement. Is that gross margin gain actually flowing through EDP, and are you in fact reinvesting all of those savings into driving top-line growth?

Jon Cox

analyst
#47

I'm curious about the kind of return profile there — you're putting so much into the EDP business to drive growth, yet on the other side profitability isn't moving, and the risk is that once you stop investing, that volume will actually revert to where it has historically been in dairy in Europe and elsewhere. Thank you.

Juergen Esser

executive
#48

Good morning. Good morning, Jon. Starting with your first question: look, this morning we've issued guidance for the full year, and we did so with a great deal of confidence. The reason we're able to give that full-year guidance with such confidence is that over the past four years we've consistently delivered on our commitments. We exited year 2025 with very strong momentum, and yes, as I described, the IMF situation will produce a one-off in Q1. That said, in recent years we've strengthened the resilience of our portfolio by drawing on a broader set of growth engines — and not just IMF — and that's why we're expressing the guidance today with confidence. Many things underpin that confidence, among them the belief that the IMF situation will progressively normalize. It's also underpinned by what I mentioned earlier — sequential acceleration, for instance in the US, and specifically there from Q2 onwards, when we'll be running against an easier set of comps for coffee creamers. On gross margin and EDP, I'll reiterate what I said earlier. We're seeing very promising dynamics in EDP. Let's not forget that we began transforming the portfolio only some two or three years ago.

Juergen Esser

executive
#49

We made it very clear this wouldn’t be a quick turnaround — it takes some time for that to happen — and we’re very happy with what we’ve seen in year 2025. We’re transforming the portfolio in Europe in a very significant way. All the innovations we’ve been putting on the shelves are working, and we’ve learned something very important from the past: if you put innovation out there and only support it for one, two, or three quarters, you’re going to lose the innovation, you’re going to lose the renovation. That’s why we’re so much committed to supporting the innovations and the core to make sure we get sustainable success, and this will also be reflected in the profit margin at some point.

Mathilde Rodié

executive
#50

Thanks, Jon. We’ll take the next question from Warren Ackerman at Barclays.

Warren Ackerman

analyst
#51

Morning Antoine, Juergen, and Mathilde — this is Warren. I'll start with medical nutrition. Can you size up how much that business grew worldwide in Q4, and if possible split out China, Europe, and North America, along with what's driving your interest in the outlook? On Kate Farms specifically, how large is it today? What kind of growth did it post in the year or the quarter, and I'd like to get a sense of how big Kate Farms could ultimately become as you scale it — I know you have ambitious plans for the brand. Second, could you speak to some of the other growth engines, such as EDP Japan? You've described it as a standout performance — can you attach some numbers to that? And I suppose one more area, just so I understand it a bit better, is out-of-home growth, especially EDP Europe; if you could put some figures on that too, that would be great. Thank you.

Antoine de Saint-Affrique

executive
#52

Morning, Warren. We’ll make this something of a duet, and perhaps begin with EDP and EDP in Japan. The genuinely interesting thing about Japan is that, over what I believe has been the past couple of years, we have consistently been growing at a rate between high single-digit and low double-digit there—and Japan is essentially an EDP business—on a foundation of strong differentiation, on a foundation of science, and on a foundation of strong claims. That really serves as an inspiration for Activia: delivering claims that demonstrate how Activia is unique compared with other yogurts, setting ourselves apart, and justifying a premium. That is a model. Incidentally, we have the same situation—it is a smaller business and it sat under Saputo—but we have the same with Activia in Australia. It is a good model for what we want to accomplish around EDP. On out-of-home and EDP: out-of-home within EDP takes two different forms. It is what you are able to do across all the hotels and restaurants in relation to fresh dairy, obviously. I think the biggest and most important development axis there is drinkables, and that holds true for dairy—you can see it in what we are doing around Oikos, which you also find in gyms and which you are starting to find in many different places—or you can see it in what we have just launched, I believe in Germany, with the Alpro meal replacer. If you have not tried it, well, we will send some to you; it is made basically to capture those people who are working through lunchtime and who, as they leave the office, visit proximity stores.

Antoine de Saint-Affrique

executive
#53

The growth we're seeing in out-of-home channels is far outpacing what we see in mass retail. Juergen?

Juergen Esser

executive
#54

Medical nutrition is actually performing quite well right now. As we exit 2025 in particular, we're seeing double-digit growth across North America, double-digit growth in China, North Asia, and Oceania, and double-digit growth in a number of emerging markets. In fact, the split is fairly even between infant medical nutrition and adult medical nutrition, yet in both areas the traction is extremely strong. It has now reached a scale where it is beginning to affect company results as well. You brought up Kate Farms — Antoine referenced it during the prepared remarks — and it is now a $500 million business.

Antoine de Saint-Affrique

executive
#55

That's our medical nutrition business.

Juergen Esser

executive
#56

Right, and I think that's something you'll see show up in North America's like-for-like results starting in Q3, once Kate Farms, Nutricia, and the full medical nutrition platform are all feeding into the numbers. As we speak, Kate Farms is in fact posting strong double-digit growth, so we're seeing the anticipated synergies come to life between the legacy platform we already had in the US and, let's say, the network access we're gaining to hospitals and the health infrastructure in that part of the region.

Antoine de Saint-Affrique

executive
#57

Perhaps to finish on the Kate Farms-Nutricia combination. As I mentioned in the prepared remarks, together the two represent half a billion dollars. Somewhere along the way, we folded Nutricia into our Kate Farms business. The way the product lines complement each other, the way customer access complements each other, the way scale complements each other is simply fantastic. There's genuine momentum in this business, and I believe it will change the game in the US.

Juergen Esser

executive
#58

Regarding Japan, as you mentioned, that's a €400 million business as we exit year 20 25, and it's growing at a strong double-digit rate. We have additional capacity coming online very soon to support this fantastic momentum, on a portfolio that is extremely focused on high protein and gut health. That's very exciting. Japan is one of the largest dairy markets in the world, which is why we are very focused on success there.

Warren Ackerman

analyst
#59

Thanks.

Mathilde Rodié

executive
#60

Thanks, Warren. Our next question comes from David Roux at Morgan Stanley.

David Roux

analyst
#61

Morning. Am I coming through okay?

Mathilde Rodié

executive
#62

Yes.

Antoine de Saint-Affrique

executive
#63

Morning to you, David.

David Roux

analyst
#64

Thanks. Morning, everyone. First off, I want to ask about the North America yogurt capacity that you brought up. Could you update us on where things stand with that rollout right now, how much additional headroom for total US capacity it will provide once it's finished, and how we ought to view capex for the group developing from here? My second question concerns working capital. In the release, you noted working capital sitting at record lows compared with sales. I believe you referenced some destocking of Mizone, but maybe you could share a little detail on what has been behind that, and how we should view the working capital-to-sales ratio going forward? And my final question, quickly, on FX. I realize you typically don't comment on this, but since FX proved a significant factor over the past year, could you offer some expectation regarding the FX effect on revenue and EPS, at current levels, for the year ahead? Thank you.

Antoine de Saint-Affrique

executive
#65

I believe most of that question should go to Juergen. Regarding North America, the capacity is quite literally arriving in stages, one step at a time. We keep adding line upon line upon line essentially to meet demand that remains absolutely buoyant, and to be able to expand our offering again. Clearly, the capex we put in is not solely behind EDP or behind yogurts; we also invest capex in medical nutrition, as you heard last year, with what we're doing in France, in Steenvoorde, behind our infant nutrition. We invest wherever we see growth that adds value for the company.

Juergen Esser

executive
#66

If you look at capex overall — and this is what we laid out at the CMD for chapter two of Renew Danone — capex across the company will rise somewhat. In recent years we were running just under 4%. We indicated it could reach 4.5% to back capacity investments in high protein, which applies to regions such as North America, regions such as Europe, and regions such as Japan, which I mentioned a moment ago, and also to medical nutrition, where clearly we are stepping up investment for future growth. On working capital, we're very pleased with how we closed year 2025 at -10%. I believe we are now approaching best-in-class in working capital management. In fact, the working capital gain in year 2025 comes less from stocks. It's more about a far more efficient approach to managing the balance between receivables and payables, and here we benefit from something Antoine mentioned in the preparatory remarks — the digitalization of our process flows within our Global Business Services. That really gives us a tremendous platform for the ambition of staying sustainably at a good working capital level like the one we have today.

Juergen Esser

executive
#67

Regarding currency, honestly, I wish I had the ability to forecast where exchange rates are headed in 2026. You witnessed the effect on our sales, which came in at -4% for the full year. In Q4, it was -6%. Please understand that I don't want to provide a figure, since whatever figure I provide is going to be incorrect.

David Roux

analyst
#68

That’s useful. Thanks.

Mathilde Rodié

executive
#69

Thanks, David. Our next question comes from David Hayes at Jefferies.

David Hayes

analyst
#70

Hello, and good morning. Thank you, Mathilde. Good morning to all of you. I hate to be the irritating guy who keeps hammering on the guidance subject, but I suppose I'll be that irritating guy. Let me return to it briefly, just to try to get a read on that word of confidence you used, Juergen. One of your competitors yesterday was hit by this recall, and they talked about their best estimate of the brand equity effects across the year, saying they could land at the bottom end of the range. Did you think about factoring that in, or, given your confidence, do you see no reason to add such a caveat, based on the trends and brand effects you're observing, at least at this early stage of the process? My second question is on the rest of the world. Did Ramadan provide any lift? Once again, a competitor said yesterday that it was something of a help during the period. Indonesia, of course, is a large market in that region, as I know. Is there Ramadan timing we ought to factor in that takes a little back in the first quarter of this year? Thank you.

Antoine de Saint-Affrique

executive
#71

Thanks, David. We'll do this as a bit of a duet again. At this stage, we aren't seeing any major brand or brand equity impact on IMF. There's obviously disruption on the shelf. And obviously, for a period of time, there's a sales force focused on talking with customers and replenishing the shelf. While they do that, they aren't doing other things. From a pure brand and category standpoint, nothing major has shown up at this stage. It's too early to say. We're obviously watching it very, very carefully, but I wouldn't be definitive either way. On Ramadan, to be honest, we don't comment on Ramadan moving from one week to another. Juergen, I don't know if you...

Juergen Esser

executive
#72

No, regarding Ramadan, I’d say there’s nothing to add. As for the 3% to 5% guidance, in a sense what we’re saying now is boringly consistent, and that’s been the case for four years. We feel good about the 3% to 5% guidance we launched, which was in year 2022, at the end of year 2022, and you’ve seen us deliver in that corridor very consistently, so there’s nothing to add to what I said earlier about the guidance—we feel good about it.

David Hayes

analyst
#73

Right, okay.

Mathilde Rodié

executive
#74

Thanks, David. Our final question comes from Tom Sykes at Deutsche Bank.

Tom Sykes

analyst
#75

Good morning, everyone. Thanks. First, on gross margin — it appears that it declined somewhat on a sequential basis in H2, and that's the first time in some time. Could you perhaps explain what's driving that? Is it FX, or might you comment on COGS productivity, and also on whether you'll be able to price below your COGS inflation as you've been doing? And then on high protein growth, whether in North America or globally, could you share a view on the current growth run rate compared with, say, where you stood in the first half of the year? Thank you.

Antoine de Saint-Affrique

executive
#76

I'll begin with high protein growth, perhaps. In the protein space, we continue to observe extremely, extremely dynamic growth. If you look at how the yogurt category is growing overall, it's highly dynamic. At the global level, I believe it's high single digit, and protein has been the driver. Protein, incidentally, comes in various forms. There's high protein, such as Oikos or YoPRO. There's also skyr, and at Danone skyr is performing extremely well, and you see that reflected too — I mentioned it in the remarks — in the figures for the Danone brands. There's a profound, profound trend around protein in its different forms, and we think that trend is here to stay. As I also said in the preparatory remarks, it is becoming more sophisticated. It isn't protein for protein's sake, but protein that does something, or protein that is complemented by something. On protein that does something, you've seen what we've launched under Oikos, with protein plus digestive benefits, what we've launched in Europe under HiPRO YoPRO, which is muscle recovery, or what we've launched behind skyr, which is a different positioning, yet one that is also very relevant when it comes to protein that fuels you in your daily activity, since you need something high in protein and low in the rest.

Antoine de Saint-Affrique

executive
#77

We believe this is a trend that will endure over the long term. Gradually, we're seeing the market move toward various types of protein, and clearly we aren't merely riding that wave — we're leading it in more than one respect.

Juergen Esser

executive
#78

Morning, Tom. Regarding gross margin, you're absolutely right that H2 expanded a bit less than H1. It's not about productivity, which really was very strong across the year. It's more about the phasing of material inflation, especially coming through from dairy ingredients, things like whey or things like lactose, which were quite high, where prices were quite high in year 2026, where we were better protected through hedging in the first semester than in the second semester. That's why we had a bit more impact in the second semester coming from it. Good news is that those prices have started to come down. Nothing particular to say for year 2026.

Mathilde Rodié

executive
#79

That brings the Q&A portion to a close. Thanks, Tom, for that final question.

Antoine de Saint-Affrique

executive
#80

Thanks, everyone, and we'll be seeing you—or most of you—soon over the next few weeks. Good day to all of you, and have a good weekend.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Danone S.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Danone S.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Danone S.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.